Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Algae represent a diverse, polyphyletic group of photosynthetic, eukaryotic organisms that range from microscopic unicellular species to large multicellular forms like kelp (Guiry, 2012). From a clinical and pharmacological perspective, 'Algae' is not a specific therapeutic target, such as a receptor or enzyme, but rather a general biological category. While most algae are ecologically beneficial, certain species are medically significant as pathogens; for example, the genus Prototheca can cause protothecosis, an opportunistic infection in humans and animals (Kambampati et al., 2018). Additionally, some algae produce secondary metabolites during harmful algal blooms (HABs) that act as potent toxins, such as saxitoxins which block voltage-gated sodium channels or microcystins which inhibit protein phosphatases (Wang, 2008). In the biotechnology industry, algae are more commonly viewed as platforms for the production of biofuels, nutraceuticals, and pharmaceutical precursors than as targets for drug development.
Not applicable; Algae is a broad group of organisms rather than a specific molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Algae.